Identification

Name
Dabigatran etexilate
Accession Number
DB06695
Type
Small Molecule
Groups
Approved
Description

Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. FDA approved on October 19, 2010.

Structure
Thumb
Synonyms
  • Dabigatran
  • Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate
External IDs
BIBR 1048 / BIBR 1048 BS RS1 / BIBR-1048 / BIBR-1048-BS-RS1
Product Ingredients
IngredientUNIICASInChI Key
Dabigatran etexilate mesilateSC7NUW5IIT872728-81-9XETBXHPXHHOLOE-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PradaxaCapsule75 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2008-07-03Not applicableCanada
PradaxaCapsule150 mgOralBoehringer Ingelheim2008-03-18Not applicableEu
PradaxaCapsule150 mg/1OralBoehringer Ingelheim2010-10-26Not applicableUs
PradaxaCapsule110 mgOralBoehringer Ingelheim2008-03-18Not applicableEu
PradaxaCapsule110 mgOralBoehringer Ingelheim2008-03-18Not applicableEu
PradaxaCapsule75 mgOralBoehringer Ingelheim2008-03-18Not applicableEu
PradaxaCapsule150 mgOralBoehringer Ingelheim2008-03-18Not applicableEu
PradaxaCapsule75 mg/1OralBoehringer Ingelheim2011-08-08Not applicableUs
PradaxaCapsule150 mgOralBoehringer Ingelheim2008-03-18Not applicableEu
PradaxaCapsule110 mg/1OralBoehringer Ingelheim2015-11-23Not applicableUs
International/Other Brands
Pradax (Boehringer Ingelheim) / Rendix
Categories
UNII
2E18WX195X
CAS number
211915-06-9
Weight
Average: 627.7332
Monoisotopic: 627.316917457
Chemical Formula
C34H41N7O5
InChI Key
KSGXQBZTULBEEQ-UHFFFAOYSA-N
InChI
InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)
IUPAC Name
ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate
SMILES
CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1

Pharmacology

Indication

Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL < 30 ml/min); haemorrhagic manifestations, bleeding diathesis or spontaneous or pharmacologic impairment of haemostasis; lesions at risk of clinically significant bleeding (e.g. extensive cerebral infarction (haemorrhagic or ischemic) in the last 6 months, active peptic ulcer disease); concomitant treatment with P-glycoprotein inhibitors (e.g. oral ketoconazole, verapamil); and those with known hypersensitivity to dabigatran, dabigatran etexilate or any ingredient used in the formulation or component of the container. As of December 2012, dabigatran is contraindicated in patients with mechanical prosthetic heart valves.

Structured Indications
Pharmacodynamics

Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran.

Mechanism of action

Dabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in the coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.

TargetActionsOrganism
AProthrombin
inhibitor
Human
Absorption

Peak plasma concentrations were achieved in 6 hours in post surgical patients. In healthy patients, maximum concentrations were achieved in 0.5 to 2 hours. The absolute bioavailability of dabigatran in the body after administration of dabigatran etexilate was 6.5%. Food does not affect the bioavailability of dabigatran etexilate, but it delays the time to peak plasma concentrations by 2 hours. Oral bioavailability may increase by up to 75% when pellets are taken out of the hydroxypropylmethylcellulose (HPMC) capsule. Therefore, capsules should not be opened and pellets taken alone. Furthermore, although absorption of dabigatran etexilate is independent of gastrointestinal acidity, coadministration of pantoprazole (proton pump inhibitor) may reduce the bioavailability of dabigatran. Despite this finding, dose adjustment is not required.

Volume of distribution

Moderate tissue distribution with a Vd of 60-70L. Accumulation factor, twice daily dosing = 2

Protein binding

Relatively low binding (34-35%) to plasma proteins.

Metabolism

CYP450 enzymes are not involved in the metabolism of dabigatran thus is not expected to interact with drugs metabolized by CYP isoenzymes. Dabigatran is typically metabolised by esterases and microsomal carboxylesterases. Pharmacologically active acylglucoronides are formed via conjugation. Four positional isomers, 1-O, 2-O, 3-O, and 4-O, acylglucuronides exist, each accounting for less than 10% of total plasma dabagatran.

Route of elimination

Mainly excreted in urine (85%). Fecal excretion accounts for 6% of the orally administered dose. Dabigatran is primarily eliminated unchanged via the kidneys at a rate of 100 ml/min corresponding to the glomerular filtration rate.

Half life

12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery.

Clearance
Not Available
Toxicity

The most common adverse reactions include dyspepsia or gastritis-like symptoms. The approximate lethal dose (LD50) in rats and mice was observed at single oral doses of > 2000 mg/kg. Oral doses of 600 mg/kg did not induce any toxicologically meaningful changes in dogs and Rhesus monkeys. Dabigatran was well-tolerated in rats and Rhesus monkeys during repeat-dose toxicity studies. No evidence of mutagenic potential.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational
AceclofenacAceclofenac may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
AcemetacinAcemetacin may increase the anticoagulant activities of Dabigatran etexilate.Approved
AcetaminophenThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Acetaminophen.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Dabigatran etexilate.Approved
AfatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Afatinib.Approved
AlbendazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Albendazole.Approved, Vet Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
AldosteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alectinib.Approved
AlfentanilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Alfentanil.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
AlgeldrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Algeldrate.Approved, Experimental
AllylestrenolThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Allylestrenol.Approved
AlmagateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Almagate.Experimental
AlmasilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Almasilate.Approved, Experimental
AlminoprofenAlminoprofen may increase the anticoagulant activities of Dabigatran etexilate.Experimental
AloglutamolThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aloglutamol.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Dabigatran etexilate.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Dabigatran etexilate.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
AltrenogestThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Altrenogest.Vet Approved
AluminiumThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium.Approved
Aluminium acetoacetateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Aluminum hydroxide.Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AmantadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amantadine.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Dabigatran etexilate.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Dabigatran etexilate.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Aminohippuric acid.Approved, Investigational
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
AmiodaroneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amitriptyline.Approved
AmlodipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amlodipine.Approved
AmprenavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amprenavir.Approved
AmsacrineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Amsacrine.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Dabigatran etexilate.Approved
AndrographolideAndrographolide may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Dabigatran etexilate.Approved
ApocyninApocynin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
ApremilastApremilast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
AprotininThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Aprotinin.Approved, Withdrawn
AstaxanthinAstaxanthin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
AstemizoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atazanavir.Approved, Investigational
AtenololThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Atenolol.Approved
AtorvastatinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Atorvastatin.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Dabigatran etexilate.Approved
AzithromycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Azithromycin.Approved
BalsalazideBalsalazide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BecaplerminDabigatran etexilate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BenorilateBenorilate may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
BenzocaineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Benzocaine.Approved
BepridilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bepridil.Approved, Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Dabigatran etexilate.Investigational
BevoniumBevonium may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BiperidenThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Biperiden.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosutinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bosutinib.Approved
BrinaseBrinase may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
BromocriptineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
BufexamacBufexamac may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BumadizoneBumadizone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
BuprenorphineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Buspirone.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Dabigatran etexilate.Investigational
CabazitaxelThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cabazitaxel.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Dabigatran etexilate.Approved
CaffeineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caffeine.Approved
Calcium CarbonateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium Carbonate.Approved
Calcium silicateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Canagliflozin.Approved
Candesartan cilexetilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan.Approved
CangrelorCangrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
CaptoprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Captopril.Approved
CarbamazepineThe metabolism of Dabigatran etexilate can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Dabigatran etexilate.Experimental, Investigational
CarprofenCarprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caspofungin.Approved
CastanospermineCastanospermine may increase the anticoagulant activities of Dabigatran etexilate.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
CertoparinDabigatran etexilate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Dabigatran etexilate.Investigational, Withdrawn
ChlorpromazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorprothixene.Approved, Investigational, Withdrawn
CholesterolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cholesterol.Experimental, Investigational
Cholic AcidThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
CilazaprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Dabigatran etexilate.Approved
CimetidineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cimetidine.Approved
CiprofloxacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Dabigatran etexilate.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Citalopram.Approved
Citric AcidDabigatran etexilate may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clomipramine.Approved, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Dabigatran etexilate.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical
CloricromenCloricromen may increase the anticoagulant activities of Dabigatran etexilate.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Dabigatran etexilate.Experimental
ClotrimazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cobicistat.Approved
ColchicineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colchicine.Approved
ColforsinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Colforsin.Experimental, Investigational
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Dabigatran etexilate.Approved
CrizotinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Crizotinib.Approved
CurcuminCurcumin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.Approved
CyclophosphamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate.Approved, Investigational, Vet Approved
D-LimoneneD-Limonene may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DaclatasvirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Daclatasvir.Approved
DactinomycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dactinomycin.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Dabigatran etexilate.Experimental
DarexabanDabigatran etexilate may increase the anticoagulant activities of Darexaban.Investigational
DasatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Daunorubicin.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Dabigatran etexilate.Approved
DemegestoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DesipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desipramine.Approved
DesloratadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Desloratadine.Approved, Investigational
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DesogestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Desogestrel.Approved
DexamethasoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DexlansoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexlansoprazole resulting in a loss in efficacy.Approved
DexrabeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Dexrabeprazole resulting in a loss in efficacy.Experimental
DextranDabigatran etexilate may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dabigatran etexilate may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dabigatran etexilate may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dabigatran etexilate may increase the anticoagulant activities of Dextran 75.Approved
DextromethorphanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dextromethorphan.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Dabigatran etexilate.Experimental
DiclofenacThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diclofenac.Approved, Vet Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Dabigatran etexilate.Experimental
DiflunisalDiflunisal may increase the anticoagulant activities of Dabigatran etexilate.Approved
DigoxinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Digoxin.Approved
DihydroergotamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dihydroergotamine.Approved
DiltiazemThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Diltiazem.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Dabigatran etexilate.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Dabigatran etexilate.Approved
DitazoleDitazole may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Dabigatran etexilate.Approved
DoxazosinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxazosin.Approved
DoxepinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxepin.Approved
DoxorubicinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Dabigatran etexilate.Investigational
DydrogesteroneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Dabigatran etexilate.Approved
E-6201E-6201 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Edetic AcidDabigatran etexilate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanDabigatran etexilate may increase the anticoagulant activities of Edoxaban.Approved
ElbasvirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Elbasvir.Approved
EnalaprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enasidenib.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
EnzalutamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Enzalutamide.Approved
EpimestrolEpimestrol may decrease the anticoagulant activities of Dabigatran etexilate.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Dabigatran etexilate.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Dabigatran etexilate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EquolEquol may decrease the anticoagulant activities of Dabigatran etexilate.Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Dabigatran etexilate.Approved
ErgonovineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergonovine.Approved
ErgotamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergotamine.Approved
ErythromycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Erythromycin.Approved, Vet Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Dabigatran etexilate.Investigational
EsomeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Esomeprazole resulting in a loss in efficacy.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Estramustine.Approved
EstriolThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Dabigatran etexilate.Approved
EstroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dabigatran etexilate.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Dabigatran etexilate.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Dabigatran etexilate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoposideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etoposide.Approved
EtoricoxibEtoricoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
EtravirineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etravirine.Approved
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
exisulindexisulind may increase the anticoagulant activities of Dabigatran etexilate.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Dabigatran etexilate.Experimental
FelodipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Dabigatran etexilate.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
FentanylThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the anticoagulant activities of Dabigatran etexilate.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
Ferulic acidDabigatran etexilate may increase the anticoagulant activities of Ferulic acid.Experimental
FexofenadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fexofenadine.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
FidaxomicinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fidaxomicin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
FluconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluconazole.Approved
FlunixinFlunixin may increase the anticoagulant activities of Dabigatran etexilate.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Dabigatran etexilate.Experimental
FluoxetineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluphenazine.Approved
FlurazepamThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Flurazepam.Approved, Illicit
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
FluvoxamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Fluvoxamine.Approved, Investigational
Fondaparinux sodiumDabigatran etexilate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateDabigatran etexilate may increase the anticoagulant activities of Gabexate.Investigational
GarlicThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Garlic.Approved
GefitinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gefitinib.Approved, Investigational
GenisteinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Genistein.Investigational
GestodeneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gestrinone.Approved
GlecaprevirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glecaprevir.Approved
GlyburideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glyburide.Approved
GlycerinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Gramicidin D.Approved
GrepafloxacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Grepafloxacin.Investigational, Withdrawn
GuacetisalGuacetisal may increase the anticoagulant activities of Dabigatran etexilate.Experimental
HaloperidolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Haloperidol.Approved
HeminHemin may increase the anticoagulant activities of Dabigatran etexilate.Approved
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Dabigatran etexilate.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Dabigatran etexilate.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
HydrocortisoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Hydrocortisone.Approved, Vet Approved
HydrotalciteThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Hydrotalcite.Experimental, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dabigatran etexilate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Dabigatran etexilate.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical
IdelalisibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Idelalisib.Approved
IdraparinuxDabigatran etexilate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Dabigatran etexilate.Investigational
IloprostIloprost may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
ImatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imatinib.Approved
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Dabigatran etexilate.Experimental
ImipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imipramine.Approved
IndinavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indinavir.Approved
IndobufenIndobufen may increase the anticoagulant activities of Dabigatran etexilate.Investigational
IndomethacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Dabigatran etexilate.Experimental
IsavuconazoniumThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Isavuconazonium.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
ItraconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivacaftor.Approved
IvermectinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ivermectin.Approved, Vet Approved
KebuzoneKebuzone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
KetamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ketamine.Approved, Vet Approved
KetanserinKetanserin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
KetoconazoleThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Dabigatran etexilate.Approved
LansoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lapatinib.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
LetaxabanDabigatran etexilate may increase the anticoagulant activities of Letaxaban.Investigational
LevofloxacinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lidocaine.Approved, Vet Approved
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dabigatran etexilate.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Dabigatran etexilate.Experimental
LiothyronineThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Dabigatran etexilate.Investigational
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Dabigatran etexilate.Experimental
LomitapideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lomitapide.Approved
LonazolacLonazolac may increase the anticoagulant activities of Dabigatran etexilate.Experimental
LoperamideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loperamide.Approved
LopinavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lopinavir.Approved
LoratadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Loratadine.Approved
LornoxicamLornoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
LosartanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Losartan.Approved
LovastatinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
LumacaftorThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
MagaldrateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Hydroxide.Approved
Magnesium oxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
Magnesium silicateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Maprotiline.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
MebendazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mebendazole.Approved, Vet Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
MefloquineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mefloquine.Approved
Megestrol acetateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
MeprobamateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate.Approved, Illicit
MesalazineMesalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Dabigatran etexilate.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Dabigatran etexilate.Investigational, Withdrawn
MethadoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Methadone.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Dabigatran etexilate.Experimental
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Dabigatran etexilate.Approved
MethylestrenoloneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Methylestrenolone.Experimental
MetoprololThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mifepristone.Approved, Investigational
MilrinoneMilrinone may increase the anticoagulant activities of Dabigatran etexilate.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Dabigatran etexilate.Approved
MitomycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mitomycin.Approved
MitoxantroneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Mitoxantrone.Approved, Investigational
MizoribineMizoribine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
MofebutazoneMofebutazone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
MorphineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Morphine.Approved, Investigational
MoxestrolMoxestrol may decrease the anticoagulant activities of Dabigatran etexilate.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Dabigatran etexilate.Approved
NafamostatDabigatran etexilate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Dabigatran etexilate.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Dabigatran etexilate.Investigational
NaltrexoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naltrexone.Approved, Investigational, Vet Approved
NaproxenNaproxen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
NaringeninThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Naringenin.Experimental
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Dabigatran etexilate.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nelfinavir.Approved
NeostigmineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Neostigmine.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Dabigatran etexilate.Approved
NicardipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nicardipine.Approved
NifedipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nifedipine.Approved
NifenazoneNifenazone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
NilotinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Nintedanib.Approved
NisoldipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nisoldipine.Approved
NitrazepamThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrazepam.Approved
NitrendipineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may increase the anticoagulant activities of Dabigatran etexilate.Investigational
NomegestrolThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Norethisterone.Approved
NorgestrienoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Norgestrienone.Experimental
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Dabigatran etexilate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Obinutuzumab.Approved
OlopatadineOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.Approved
OlsalazineOlsalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical
OmeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Omeprazole.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Dabigatran etexilate.Investigational
OrgoteinOrgotein may increase the anticoagulant activities of Dabigatran etexilate.Vet Approved
OtamixabanDabigatran etexilate may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Dabigatran etexilate.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Dabigatran etexilate.Investigational
P-NitrophenolThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pantoprazole.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
ParoxetineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Paroxetine.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Dabigatran etexilate.Investigational
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PerindoprilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Pethidine.Approved
PhenobarbitalThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
PibrentasvirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pibrentasvir.Approved
PicotamidePicotamide may increase the anticoagulant activities of Dabigatran etexilate.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PimozideThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pimozide.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Dabigatran etexilate.Experimental
Platelet Activating FactorThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.Experimental
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Dabigatran etexilate.Approved
PonatinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ponatinib.Approved
PosaconazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenPranoprofen may increase the anticoagulant activities of Dabigatran etexilate.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
PravastatinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin.Approved
PrazosinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prazosin.Approved
PrednisoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Probenecid.Approved
ProgesteroneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Dabigatran etexilate.Experimental
PromegestoneThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Dabigatran etexilate.Investigational
PromethazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Promethazine.Approved
PropacetamolPropacetamol may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
PropafenoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propafenone.Approved
PropranololThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
Protein S humanDabigatran etexilate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDabigatran etexilate may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline.Approved
PTC299PTC299 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
QuercetinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinacrine.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Dabigatran etexilate.Approved
QuinidineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Quinine.Approved
RabeprazoleThe serum concentration of the active metabolites of Dabigatran etexilate can be reduced when Dabigatran etexilate is used in combination with Rabeprazole resulting in a loss in efficacy.Approved, Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Dabigatran etexilate.Investigational
RanitidineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ranitidine.Approved
RanolazineThe serum concentration of Dabigatran etexilate can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Regorafenib.Approved
ReserpineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Reserpine.Approved, Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Dabigatran etexilate.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
RidogrelRidogrel may increase the anticoagulant activities of Dabigatran etexilate.Approved
RifampicinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rifampicin.Approved
RilpivirineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rilpivirine.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Dabigatran etexilate.Approved
RitonavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ritonavir.Approved, Investigational
RofecoxibRofecoxib may increase the anticoagulant activities of Dabigatran etexilate.Investigational, Withdrawn
RolapitantThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Rolapitant.Approved
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Dabigatran etexilate.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Dabigatran etexilate.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Dabigatran etexilate.Approved
SaquinavirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Saquinavir.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Dabigatran etexilate.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Dabigatran etexilate.Experimental
ScopolamineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Scopolamine.Approved
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Dabigatran etexilate.Investigational
SelegilineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Selegiline.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Dabigatran etexilate.Approved
SemapimodSemapimod may increase the anticoagulant activities of Dabigatran etexilate.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Dabigatran etexilate.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Dabigatran etexilate.Investigational
SertralineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sertraline.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Dabigatran etexilate.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
SimeprevirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Simeprevir.Approved
SimvastatinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Simvastatin.Approved
SirolimusThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Dabigatran etexilate.Investigational
St. John's WortThe metabolism of Dabigatran etexilate can be increased when combined with St. John&#39;s Wort.Investigational, Nutraceutical
StaurosporineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Staurosporine.Experimental
StreptokinaseStreptokinase may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
StreptozocinThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulfinpyrazoneSulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.Approved
SulindacSulindac may increase the anticoagulant activities of Dabigatran etexilate.Approved
SumatriptanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Dabigatran etexilate.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Dabigatran etexilate.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate.Approved
TacrineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tacrine.Investigational, Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Dabigatran etexilate.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tamoxifen.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Dabigatran etexilate.Investigational
Taurocholic AcidThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telaprevir.Approved, Withdrawn
TelmisartanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Temsirolimus.Approved
TenecteplaseTenecteplase may increase the anticoagulant activities of Dabigatran etexilate.Approved
TenidapTenidap may increase the anticoagulant activities of Dabigatran etexilate.Experimental
TenoxicamTenoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Dabigatran etexilate.Vet Approved
TerazosinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terazosin.Approved
TerfenadineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may increase the anticoagulant activities of Dabigatran etexilate.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Dabigatran etexilate.Investigational
TestosteroneThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Testosterone.Approved, Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Dabigatran etexilate.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Dabigatran etexilate.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
TiboloneTibolone may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Dabigatran etexilate.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Dabigatran etexilate.Approved
TinoridineTinoridine may increase the anticoagulant activities of Dabigatran etexilate.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Dabigatran etexilate.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Dabigatran etexilate.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Dabigatran etexilate.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
TolmetinTolmetin may increase the anticoagulant activities of Dabigatran etexilate.Approved
TolvaptanThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Tolvaptan.Approved
TositumomabThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Dabigatran etexilate.Approved
TrazodoneThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.Approved, Investigational
TreprostinilTreprostinil may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Dabigatran etexilate.Approved
TribenosideTribenoside may increase the anticoagulant activities of Dabigatran etexilate.Experimental
TrifluoperazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trifluoperazine.Approved
TriflupromazineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Triflupromazine.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
TrimethoprimThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Trimipramine.Approved
TriptolideTriptolide may increase the anticoagulant activities of Dabigatran etexilate.Investigational
TroleandomycinThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Troleandomycin.Approved
TroxerutinDabigatran etexilate may increase the anticoagulant activities of Troxerutin.Investigational
ValdecoxibValdecoxib may increase the anticoagulant activities of Dabigatran etexilate.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Dabigatran etexilate.Approved, Investigational
VelpatasvirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Velpatasvir.Approved
VenlafaxineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Venlafaxine.Approved
VerapamilThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Verapamil.Approved
VinblastineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinblastine.Approved
VincristineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vinorelbine.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Dabigatran etexilate.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Dabigatran etexilate.Approved
VoxilaprevirThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Voxilaprevir.Approved
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Dabigatran etexilate.Vet Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Dabigatran etexilate.Approved
ZileutonZileuton may increase the anticoagulant activities of Dabigatran etexilate.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Zimelidine.Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Dabigatran etexilate.Withdrawn
Food Interactions
  • St. John's Wort

References

Synthesis Reference

Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban, "METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE." U.S. Patent US20110118471, issued May 19, 2011.

US20110118471
General References
  1. Bauer KA: New oral anticoagulants in development: potential for improved safety profiles. Rev Neurol Dis. 2010;7(1):1-8. [PubMed:20410856]
  2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. [PubMed:19717844]
  3. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI: Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009 Jan;101(1):77-85. [PubMed:19132192]
  4. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA: Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. doi: 10.1016/j.arth.2008.01.132. Epub 2008 Apr 14. [PubMed:18534438]
  5. Eriksson BI, Dahl OE, Buller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005 Jan;3(1):103-11. [PubMed:15634273]
  6. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N Engl J Med. 2005 Sep 8;353(10):1028-40. [PubMed:16148288]
  7. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005 May;45(5):555-63. [PubMed:15831779]
  8. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, Pedersen KE, Lionetti DA, Stangier J, Wallentin L: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007 Nov 1;100(9):1419-26. Epub 2007 Aug 17. [PubMed:17950801]
  9. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85. [PubMed:17764540]
  10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. [PubMed:17869635]
  11. Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752]
External Links
Human Metabolome Database
HMDB15641
KEGG Drug
D07144
PubChem Compound
6445226
PubChem Substance
99443249
ChemSpider
4948999
BindingDB
50432209
ChEBI
70746
ChEMBL
CHEMBL539697
PharmGKB
PA165958369
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Dabigatran
ATC Codes
B01AE07 — Dabigatran etexilate
AHFS Codes
  • 20:12.04.12 — Direct Thrombin Inhibitors
FDA label
Download (431 KB)
MSDS
Download (99.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherProstatic Neoplasms1
1Active Not RecruitingTreatmentHealthy Volunteers1
1CompletedNot AvailableCardiovascular Disease (CVD) / Kidney Failure,Chronic1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceDisorders, Blood Coagulation1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentHealthy Volunteers24
1CompletedTreatmentHepatic Insufficiency1
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentNon-Alcoholic Fatty Liver Disease (NAFLD)1
1CompletedTreatmentRenal Insufficiency,Chronic1
1CompletedTreatmentThrombosis1
1RecruitingTreatmentInterstitial Lung Disease (ILD) / Scleroderma1
1TerminatedTreatmentHealthy Volunteers1
1Unknown StatusBasic ScienceHealthy Volunteers1
2CompletedNot AvailableVenous Thromboembolism1
2CompletedPreventionArthroplasty, Replacement, Knee / Thrombosis, Venous1
2CompletedPreventionNonvalvular Atrial Fibrillation1
2CompletedPreventionVenous Thromboembolism1
2CompletedTreatmentCoronary Heart Disease (CHD)1
2CompletedTreatmentVenous Thromboembolism3
2RecruitingTreatmentMinor Ischemic Stroke / Transient Ischaemic Attack (TIA)1
2TerminatedPreventionHeart Valve Diseases1
2TerminatedPreventionHeart Valve Prosthesis / Thromboembolism1
2TerminatedPreventionNonvalvular Atrial Fibrillation / Strokes1
2TerminatedTreatmentHaemorrhage / Thrombosis1
2Unknown StatusTreatmentCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy1
2WithdrawnTreatmentVenous Thromboembolism1
2, 3TerminatedTreatmentPrimary Disease1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedPreventionArthroplasty, Replacement, Hip / Thromboembolism1
3CompletedPreventionArthroplasty, Replacement, Knee / Thromboembolism2
3CompletedPreventionVenous Thromboembolism1
3CompletedTreatmentNonvalvular Atrial Fibrillation / Percutaneous Coronary Intervention1
3CompletedTreatmentThromboembolism3
3Not Yet RecruitingPreventionAtrial Flutter / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Nonvalvular Atrial Fibrillation / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma1
3Not Yet RecruitingTreatmentCerebral Venous Thrombosis1
3Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
3RecruitingPreventionSecondary Preventions / Strokes1
3RecruitingPreventionSecondary Preventions / Venous Thromboembolism1
3RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1
3RecruitingTreatmentHematoma1
3RecruitingTreatmentThromboembolism1
3RecruitingTreatmentVenous Thromboembolism1
3Unknown StatusPreventionVenous Thromboembolism1
4Active Not RecruitingSupportive CareAtrial Flutter / Nonvalvular Atrial Fibrillation1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedPreventionArthroplasty, Replacement / Moderate Renal Impairment (CrCl 30-50 mL/Min) / Prevention of Venous Thromboembolism1
4CompletedPreventionNonvalvular Atrial Fibrillation2
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentNonvalvular Atrial Fibrillation4
4Enrolling by InvitationTreatmentNonvalvular Atrial Fibrillation1
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation / Valve Heart Disease1
4RecruitingOtherCerebral Ischemic Events / Cognition Disorders / Dementias1
4RecruitingPreventionNonvalvular Atrial Fibrillation2
4RecruitingTreatment(Atrial Fibrillation) or (Atrial Flutter) / Thrombosis of Left Atrial Appendage1
4RecruitingTreatmentAngiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy / Dabigatran Etexilate / Prophylaxis of Pulmonary embolism / Recurrence of DVT / Warfarin1
4RecruitingTreatmentCardioembolic Events / Nonvalvular Atrial Fibrillation / Oral Anticoagulation1
4RecruitingTreatmentDeep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism1
4RecruitingTreatmentLeft Atrial Thrombosis / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentNonvalvular Atrial Fibrillation2
4RecruitingTreatmentProphylaxis of Pulmonary embolism1
4TerminatedDiagnosticNonvalvular Atrial Fibrillation1
4TerminatedTreatmentAcute Coronary Syndromes (ACS) / Atherosclerosis / Coronary Heart Disease (CHD) / Nonvalvular Atrial Fibrillation1
4Unknown StatusNot AvailableAnticoagulant Overdosage / Anticoagulant-induced Bleeding / Hemorrhage / Thrombosis1
4WithdrawnTreatmentCoronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina (UA)1
4WithdrawnTreatmentThromboembolism1
Not AvailableActive Not RecruitingNot AvailableNonvalvular Atrial Fibrillation2
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation4
Not AvailableCompletedNot AvailableNonvalvular Atrial Fibrillation / Strokes Thrombotic1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableCompletedTreatmentNonvalvular Atrial Fibrillation1
Not AvailableNot Yet RecruitingNot AvailableNonvalvular Atrial Fibrillation1
Not AvailableRecruitingNot AvailableIschemic Attack, Transient / Strokes1
Not AvailableRecruitingNot AvailableNonvalvular Atrial Fibrillation2
Not AvailableRecruitingNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableRecruitingSupportive CareHemorrhage / Nonvalvular Atrial Fibrillation / Periodontal Diseases1
Not AvailableRecruitingTreatmentAnticoagulant Adverse Reaction / Hemorrhage / Nonvalvular Atrial Fibrillation / Thrombosis1
Not AvailableRecruitingTreatmentBlood Clots / Cancers / Deep Vein Thrombosis (DVT) / Prophylaxis of Pulmonary embolism / Venous Thromboembolism1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral110 mg
CapsuleOral110 mg/1
CapsuleOral150 mg/1
CapsuleOral150 mg
CapsuleOral75 mg
CapsuleOral75 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US9034822No2011-01-202031-01-20Us
US6087380No1998-02-182018-02-18Us
US7932273No2005-09-072025-09-07Us
US7866474No2007-08-312027-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)180 +/- 3 (DSC: 10 K min^-1 heating rate)Not Available
water solubility1.8mg/ml, partly soluble MSDS
logP3.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00466 mg/mLALOGPS
logP5.17ALOGPS
logP4.59ChemAxon
logS-5.1ALOGPS
pKa (Strongest Acidic)17.89ChemAxon
pKa (Strongest Basic)3.87ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area154.03 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity176.43 m3·mol-1ChemAxon
Polarizability71.11 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.942
Blood Brain Barrier+0.8673
Caco-2 permeable-0.7014
P-glycoprotein substrateSubstrate0.7412
P-glycoprotein inhibitor IInhibitor0.7539
P-glycoprotein inhibitor IIInhibitor0.8443
Renal organic cation transporterNon-inhibitor0.701
CYP450 2C9 substrateNon-substrate0.858
CYP450 2D6 substrateNon-substrate0.837
CYP450 3A4 substrateSubstrate0.6154
CYP450 1A2 substrateNon-inhibitor0.6906
CYP450 2C9 inhibitorNon-inhibitor0.5102
CYP450 2D6 inhibitorNon-inhibitor0.8417
CYP450 2C19 inhibitorInhibitor0.5157
CYP450 3A4 inhibitorInhibitor0.781
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5789
Ames testNon AMES toxic0.6292
CarcinogenicityNon-carcinogens0.8065
BiodegradationNot ready biodegradable0.9931
Rat acute toxicity2.7093 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9047
hERG inhibition (predictor II)Inhibitor0.6181
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00kk-0981100000-78856b63936cf67ebce2
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004r-0292116000-55b368cbe92da888e681

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzimidazoles
Sub Class
Not Available
Direct Parent
Benzimidazoles
Alternative Parents
Phenylalkylamines / Aniline and substituted anilines / Secondary alkylarylamines / Pyridines and derivatives / N-substituted imidazoles / Imidolactams / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives / Carboxylic acid esters
show 10 more
Substituents
Benzimidazole / Aniline or substituted anilines / Phenylalkylamine / Secondary aliphatic/aromatic amine / Aralkylamine / Monocyclic benzene moiety / N-substituted imidazole / Pyridine / Benzenoid / Imidolactam
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
carboxylic ester, carboxamidine, beta-alanine derivative, pyridines, aromatic amide, benzimidazoles (CHEBI:70746)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thrombospondin receptor activity
Specific Function
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostas...
Gene Name
F2
Uniprot ID
P00734
Uniprot Name
Prothrombin
Molecular Weight
70036.295 Da
References
  1. Squizzato A, Dentali F, Steidl L, Ageno W: New direct thrombin inhibitors. Intern Emerg Med. 2009 Dec;4(6):479-84. doi: 10.1007/s11739-009-0314-8. Epub 2009 Sep 15. [PubMed:19756950]
  2. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37. [PubMed:17061960]
  3. Karthikeyan G, Eikelboom JW, Hirsh J: Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010 Apr;120(4):137-42. [PubMed:20424539]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Triglyceride lipase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acy...
Gene Name
CES1
Uniprot ID
P23141
Uniprot Name
Liver carboxylesterase 1
Molecular Weight
62520.62 Da
References
  1. Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Methylumbelliferyl-acetate deacetylase activity
Specific Function
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and ...
Gene Name
CES2
Uniprot ID
O00748
Uniprot Name
Cocaine esterase
Molecular Weight
61806.41 Da
References
  1. Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14. [PubMed:23239178]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
Gene Name
UGT2B15
Uniprot ID
P54855
Uniprot Name
UDP-glucuronosyltransferase 2B15
Molecular Weight
61035.815 Da
References
  1. Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15. [PubMed:20551237]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Nadph dehydrogenase (quinone) activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
Gene Name
NQO2
Uniprot ID
P16083
Uniprot Name
Ribosyldihydronicotinamide dehydrogenase [quinone]
Molecular Weight
25918.4 Da
References
  1. Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J Med Chem. 2012 Apr 26;55(8):3934-44. doi: 10.1021/jm3001339. Epub 2012 Apr 17. [PubMed:22494098]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants. J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8. [PubMed:21327511]
  2. Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9. [PubMed:23292752]

Drug created on May 03, 2010 12:25 / Updated on November 13, 2017 21:49